Expertise in
12
conditions

Dr. Daniel Flora

Hematology | Oncology
Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, 
Edgewood, KY 
Accepting New Patients
Expertise in
12
conditions
Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, 
Edgewood, KY 

Overview

Daniel Flora is a Hematologist and an Oncologist practicing medicine in Edgewood, Kentucky.

Dr. Flora is highly rated in 12 conditions, according to our data. His clinical expertise encompasses Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, Muscle Invasive Bladder Cancer, and Myelodysplastic Syndrome (MDS).

He is actively involved in clinical research, co-authoring 14 peer reviewed articles and participating in 11 clinical trials. Dr. Flora is currently accepting new patients.

Specialties

Hematology
Oncology

Licenses

Internal Medicine in IN

Hospital Affiliations

St Elizabeth Florence
St Elizabeth Edgewood
St Elizabeth Ft Thomas

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Health Services
  • EPO
  • MANAGED MEDICAID PLAN
  • OTHER COMMERCIAL
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Mutual
  • HMO
  • PPO
SelectHealth
  • HMO
  • POS
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare
1 Medical Village Dr, Edgewood, KY 41017
Other Locations
Oncology-Ft. Thomas-St. Elizabeth Healthcare
85 N Grand Ave, Fort Thomas, KY 41075
Saint Elizabeth Cancer Care Medical Oncology
1 Medical Village Dr, Edgewood, KY 41017

Additional Areas of Focus

Dr. Flora has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Phase: Not Applicable
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Entinostat, Exemestane, Goserelin, Goserelin Acetate
Study Phase: Phase 3
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: July 27, 2026
Intervention Type: Drug
Study Drugs: Capecitabine, Carboplatin, Cisplatin
Study Phase: Phase 3
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2026
Intervention Type: Other, Drug
Study Drug: Erlotinib Hydrochloride
Study Phase: Phase 3
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: May 29, 2026
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Paclitaxel
Study Phase: Phase 3
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti-HER2 Therapy + Endocrine Therapy After Induction Treatment for Hormone Receptor Positive (HR+)/HER2-Positive Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 12, 2026
Intervention Type: Drug
Study Drugs: Palbociclib, Trastuzumab, Pertuzumab, Letrozole, Anastrozole, Exemestane, Fulvestrant
Study Phase: Phase 3
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Enrollment Status: Active_not_recruiting
Publish Date: December 19, 2025
Intervention Type: Other, Drug
Study Drug: Crizotinib
Study Phase: Phase 3
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes
A Phase III, Double-Blind, Controlled Trial of Oxybutynin in the Management of Hot Flashes
Enrollment Status: Completed
Publish Date: January 18, 2020
Intervention Type: Other, Drug
Study Phase: Phase 3
View 9 Less Clinical Trials

14 Total Publications

Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.
Longitudinal ctDNA Monitoring for Postsurgical Disease Surveillance in Patients with Stage I to IIIB Melanoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: October 02, 2025
Similar Doctors
Expertise in
38
conditions
Dr. Miguel A. Islas-Ohlmayer
Hematology | Oncology
Expertise in
38
conditions
Dr. Miguel A. Islas-Ohlmayer
Hematology | Oncology
Referral may be required

Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare

1 Medical Village Dr, 
Edgewood, KY 
 (6.8 miles away)
859-301-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Miguel Islas-Ohlmayer is a Hematologist and an Oncologist practicing medicine in Edgewood, Kentucky. Dr. Islas-Ohlmayer is highly rated in 38 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, Multiple Myeloma, B-Cell Lymphoma, Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Islas-Ohlmayer is currently accepting new patients.

Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required

Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare

1 Medical Village Dr, 
Edgewood, KY 
 (6.8 miles away)
859-301-4000
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Minsig Choi is an Oncologist practicing medicine in Edgewood, Kentucky. Dr. Choi is highly rated in 11 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Familial Colorectal Cancer, and Gamma Knife Radiosurgery. Dr. Choi is currently accepting new patients.

Expertise in
31
conditions
Expertise in
31
conditions
Referral may be required

Oncology-Edgewood Cancer Center-St. Elizabeth Healthcare

1 Medical Village Dr, 
Edgewood, KY 
 (6.8 miles away)
859-301-4000
Languages Spoken:
English, Hindi, Spanish
See accepted insurances
Accepting New Patients

Manish Bhandari is an Oncologist practicing medicine in Edgewood, Kentucky. Dr. Bhandari is highly rated in 31 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Adult Soft Tissue Sarcoma, Bone Graft, and Vertebroplasty. Dr. Bhandari is currently accepting new patients.

Expertise in
18
conditions
Expertise in
18
conditions
Referral may be required

SeMc Medical Village Pharmacy

20 Medical Village Dr, 
Edgewood, KY 
 (6.7 miles away)
859-301-4000
Languages Spoken:
English
See accepted insurances

Lawrence Brennan is an Oncologist practicing medicine in Edgewood, Kentucky. Dr. Brennan is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Thrombocytopenia, Lung Cancer, Pleuropulmonary Blastoma, Chronic Lymphocytic Leukemia (CLL), and Bone Marrow Aspiration.

Expertise in
22
conditions
Dr. Christy Sapp
Hematology | Oncology
Expertise in
22
conditions
Dr. Christy Sapp
Hematology | Oncology
Referral may be required

Saint Elizabeth Cancer Care Medical Oncology

1 Medical Village Dr, 
Edgewood, KY 
 (6.8 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christy Sapp is a Hematologist and an Oncologist practicing medicine in Edgewood, Kentucky. Dr. Sapp is highly rated in 22 conditions, according to our data. Her clinical expertise encompasses Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, Lung Cancer, and Myelodysplastic Syndrome (MDS). Dr. Sapp is currently accepting new patients.

Expertise in
9
conditions
Expertise in
9
conditions
Referral may be required

St Elizabeth Medical Center Inc

1 Medical Village Dr, 
Edgewood, KY 
 (6.8 miles away)
859-301-2237
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Kevin Schuler is an Oncologist practicing medicine in Edgewood, Kentucky. Dr. Schuler is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Endometrial Cancer, Malignant Mixed Mullerian Tumor, Eccrine Porocarcinoma, Hernia Surgery, and Lymphadenectomy. Dr. Schuler is currently accepting new patients.

Frequently Asked Questions about Dr. Daniel Flora

How do I make an appointment with Dr. Daniel Flora?

You can book an appointment with Dr. Daniel Flora by calling their office at 859-301-4000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Daniel Flora a top-rated expert for Chronic Myelogenous Leukemia (CML)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Daniel Flora is classified as an Advanced expert for Chronic Myelogenous Leukemia (CML), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Daniel Flora specialize in?

While Dr. Daniel Flora is a Hematology, they have specific expertise in Chronic Myelogenous Leukemia (CML), Philadelphia-Negative Chronic Myeloid Leukemia, and Muscle Invasive Bladder Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Daniel Flora participate in research or clinical trials?

Yes. Dr. Daniel Flora has published 14 articles and abstracts on conditions like Chronic Myelogenous Leukemia (CML). You can view a list of Dr. Daniel Flora's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Daniel Flora accept my insurance?

Dr. Daniel Flora accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 859-301-4000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Flora's expertise for a condition
ConditionClose
      View All 12 Advanced Conditions
      View All 38 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile